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ABSTRACT
Chimerism analysis of hematopoietic cells has emerged as an essential tool in nonmyeloablative hematopoietic
stem cell transplantation. We have investigated the development of donor chimerism in granulocytes and
CD4 and CD8T cells in blood and bone marrow of 24 patients with hematologic malignancies who received
HLA-identical sibling peripheral blood stem cell grafts after conditioning with fludarabine and 2 Gy of total
body irradiation. The T-cell chimerism of blood and bone marrow was tightly correlated. Complete donor
chimerism was reached earlier in the granulocytes than in the T cells. Mixed T-cell chimerism was common
at the time of onset of acute graft-versus-host disease (aGVHD), and both CD4 and CD8 donor T-cell
chimerism increased with the occurrence of aGVHD grades II to IV (P  .0002 and P  .019, respectively).
The rate of disappearance of recipient CD8 T cells was faster in patients with aGVHD grades II to IV than
in patients without clinically significant aGVHD (P  .016). This observation indicates a role of graft-versus-
lymphohematopoietic tissue reactions in creating complete donor T-cell chimerism. A donor CD8 T-cell
count above the median on day 14 increased the risk of subsequent development of aGVHD grades II to IV
(P  .003).
© 2004 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Conditioning regimens that are nonmyeloablative
r have reduced intensity have extended the use of
llogeneic hematopoietic stem cell transplantation
HSCT) to patients who, because of older age or
omorbidity, were previously ineligible for this poten-
ially curative treatment [1-10]. In nonmyeloablative
SCT (NST), the eradication of the malignant dis-
ase is dependent on a graft-versus-tumor (GVT) ef-
ect, and there is a gradual change from recipient to
onor hematopoiesis. Determination of the level of
onor chimerism of subpopulations of leukocytes se- n
B & M Tuentially after transplantation is therefore an inte-
rated part of NST, and clinical interventions such as
hanges in the pharmacologic immunosuppression or
onor lymphocyte infusions (DLI) may depend on
himerism status [11]. Graft-versus-host disease
GVHD) is a signiﬁcant complication of NST and in
ome studies is a major cause of nonrelapse mortality
6,7,9,12]. Furthermore, GVHD may occur as a com-
lication of DLI. If the occurrence of GVHD could
e predicted, individually tailored immunosuppres-
ion might subsequently improve the treatment re-
ults. Whether complete donor T-cell chimerism is
eeded before alloresponses such as GVHD or the
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3VT effect can occur is a matter of controversy.
hilds et al. [3] found that complete donor T-cell
himerism preceded the occurrence of GVHD and
isease responses, whereas Mattsson et al. [13] ob-
erved both GVHD and disease responses in the con-
ext of mixed chimerism. We have analyzed the kinet-
cs of the development of donor chimerism in
ranulocytes and CD4 and CD8 T cells in both
eripheral blood (PB) and bone marrow (BM) in pa-
ients conditioned with a nonmyeloablative regimen
f ﬂudarabine 30 mg/m2 for 3 days and 2 Gy of total
ody irradiation (TBI) [6,14]. We observed that most
f the patients were mixed T-cell chimeras when they
xperienced acute GVHD (aGVHD), and an increase
n donor T-cell chimerism was observed during the
eriod when the patients had aGVHD. In addition,
e found that the day 14 donor CD8 T-cell count
ad predictive value for the subsequent development
f aGVHD.
ATERIALS AND METHODS
atients
Twenty-four patients received an NST with PB
able 1. Patient Characteristics
Patient
No. Diagnosis
Age, R/D
(y)
Sex
(R/D)
No. Previous
Chemotherapy
Regimens
628 NHL  t-MDS, RA 45/44 F/F 4
633 NHL 52/55 M/F 7
636 CLL 56/52 M/M 5
645 NHL 46/52 M/M 5
650 MM 42/40 M/M 2
656 t-MDS, RA 56/53 M/M 1
662 NHL 55/51 M/M 6
666 NHL 57/60 F/F 7
669 SLL 49/53 M/M 2
674 AML 27/29 F/M 3
682 CLL 57/58 M/F 7
688 T-NHL 34/41 M/F 3
692 T-NHL 37/43 M/F 2
694 NHL 51/57 M/F 10
708 MM 59/57 M/M 4
715 t-MDS, RAEB 51/49 F/F 1
723 NHL  t-MDS, RA 49/43 M/M 6
733 MM 63/52 M/F 3
741 HD 34/36 F/M 5
749 MM 47/41 M/M 2
760 MM 51/45 F/F 4
766 CLL 57/68 M/F 5
773 MM 51/56 F/M 4
780 HD 42/44 M/F 7
HL indicates non-Hodgkin lymphoma; t-MDS, therapy-related m
cytic leukemia; MM, multiple myeloma; SLL, small lymphocytic
lymphoma; HD, Hodgkin disease; RAEB, refractory anemia w
poietic stem cell transplantation; CSP, cyclosporine; aGVHD,tem cells (PBSC) from HLA-identical sibling donors m
38etween March 2000 and October 2002. Patients aged
8 to 70 years with hematologic malignancies were
ligible for NST if they—because of diagnosis, co-
orbidity, or age—were considered to have a high
reatment-related mortality with conventional HSCT.
he median age of the patients was 51 years at the
ime of transplantation. They were generally heavily
retreated and had received a median of 4 chemother-
py regimens before the NST. Twelve patients had
reviously undergone autologous stem cell transplan-
ation (Table 1). Written, informed consent was ob-
ained from all patients and donors enrolled in the
tudy. The study was approved by the local ethics
ommittee.
onditioning Regimen and GVHD Prophylaxis
The patients underwent transplantation with a
onditioning regimen that consisted of 2 Gy of TBI
n day 0 (patients 628, 636, and 674) or ﬂudarabine 30
g/m2 intravenously once daily on day 4 to day 2
nd 2 Gy of TBI on day 0 (for the remaining 21
atients) [6,14]. Oral mycophenolate mofetil 30 mg/
g/d was initiated on day 0 and discontinued on day
27 in the absence of GVHD. Oral cyclosporine 12.5
.
o
CD3
Cells
(108/kg)
Graft
CD4/CD8
T-Cell Ratio
CD34
Cells
(106/kg)
CSP Taper
before Day
100
(Start Day)
aGVHD
Grade/
Day
5.9 2.7 2.8 II/38
3.8 2.0 8.9 35 II/77
5.0 3.4 11.6 35 II/40
3.1 2.5 5.9 35 II/41
5.1 2.3 5.7 II/34
3.6 2.2 8.9 IV/33
3.2 1.9 7.1 IV/21
ND ND 3.1 I/18
3.6 2.5 14.2 I/35
3.7 1.2 28.8 III/7
2.2 3.8 4.7 68 I/45
4.3 2.4 4.5 0/—
3.0 ND 9.5 47 0/—
3.6 1.2 11.4 III/54
3.7 2.0 6 56 0/—
2.8 2.7 4.8 63 0/—
4.9 2.7 4.7 56 0/—
4.4 3.4 7.7 II/47
6.8 2.4 21.7 73 II/31
3.2 1.9 3.8 91 0/—
ND ND 6.5 II/31
ND ND 2.6 II/31
5.1 2.7 14.4 63 0/—
3.3 1.9 4.7 II/29
ysplastic syndrome; RA, refractory anemia; CLL, chronic lympho-
oma; AML, acute myeloid leukemia; T-NHL, T-cell non-Hodgkin
ess of blasts; R/D, recipient/donor; Auto Tx, autologous hemato-
raft-versus-host disease; ND, not done.No
Aut
Tx
1
0
0
2
1
0
0
1
0
0
0
0
0
0
1
0
1
1
1
1
2
0
2
2
yelod
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acute gg/kg/d was initiated on day 3. In the absence of
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Donor CD8 T-Cell Count on Day 14 Predicts Risk of Acute GVHD
BVHD, cyclosporine taper was planned to begin on
ay 35 in patients 628 to 674 and on day 56 in
atients 682 to 780. DLI in increasing doses starting
t 1  103 CD3 cells per kilogram could be given
fter day 56 to increase the donor T-cell chimerism
r as treatment of progression or relapse of the ma-
ignant disease. GVHD was graded according to stan-
ard criteria [15].
obilization of PBSC
The donors received ﬁlgrastim 16 g/kg/d from
ay 4 to day 0. Leukapheresis was performed on
ays 1 and 0, and both leukapheresis products were
iven to the patient. The graft contents of CD3 T
ells, CD4 T cells (CD3, CD4, and CD8),
D8 T cells (CD3, CD8, and CD4), and
D34 cells were quantiﬁed by use of monoclonal
ntibodies (Becton Dickinson Immunocytometry Sys-
ems, San Jose, CA) and 3-color ﬂow cytometry. The
edian cell numbers infused per kilogram of recipient
eight were as follows: 3.7 108 CD3T cells, 2.5
08 CD4 T cells, 1.15  108 CD8 T cells, and
.25  106 CD34 cells (Table 1).
-Cell Counts
TruCOUNT tubes and monoclonal antibodies
btained from Becton Dickinson were used to quan-
ify the absolute numbers of CD4 T cells and CD8
cells in the PB by 3-color ﬂow cytometry. Five
housand beads were analyzed in each sample. The
ormal values were obtained from 51 healthy donors
ith a median age of 43 years (range, 16-62 years)
16].
ell Separation and DNA Extraction
Ten milliliters of PB or 3 ml of BM was used for
himerism analysis. BM samples were obtained
onthly during the ﬁrst 4 months after transplanta-
ion and thereafter at longer intervals. The separation
f T-cell subsets for DNA extraction was performed
ither by isolation of the mononuclear cells by gradi-
nt centrifugation (Lymfoprep; Pharmacia, Peapack,
J) and puriﬁcation of the T-cell subsets from the
ononuclear cells with anti-CD4 and anti-CD8 im-
unomagnetic beads (Dynabeads; Dynal, Oslo, Nor-
ay) or by direct isolation of CD4 T cells and CD8
cells from whole blood with the immunomagnetic
eads. The chimerism analysis of granulocytes was
erformed either on DNA extracted from the pellet
btained from gradient centrifugation or on CD15
ells isolated directly from whole blood with anti-
D15 immunomagnetic beads (Dynabeads). Potential
ontamination of the separated T cells with CD4
onocytes (CD4, CD14, and CD3) or CD8
atural killer cells (CD8, CD16, CD56, and
D3 ) was examined by 3-color ﬂow cytometry and 6
B & M Tas3% in the CD4 T-cell population and1% in
he CD8 T-cell population with both separation
ethods (data not shown). DNA was isolated from
ach cell population by NaCl extraction [17].
himerism Analysis
The level of donor chimerism was determined by
uorescence-based polymerase chain reaction (PCR)
f short tandem repeats [18]. Separation and detection
f the ampliﬁed PCR products was performed on an
utomated 310 Genetic Analyzer (Applied Biosystems,
oster City, CA), and the results were analyzed with
eneScan software (Applied Biosystems). The detec-
ion limit of the method was generally 1%, but varying
ignal intensity of the primers increased the detection
imit to 5% in 26 of 823 analyzed DNA samples and to
0% in 3 samples. Complete donor chimerism was
eﬁned as the absence of detectable PCR fragments of
atient origin. This implied that in the vast majority of
amples, mixed chimerism was deﬁned as 1% to 99%
onor cells, and complete donor chimerism was de-
ned as 99% donor cells.
tatistical Methods
Time-dependent variables were analyzed by the
ethod of Kaplan and Meier, and the cumulative
ncidences were compared by using the log-rank test.
ategorical variables were compared by using the
isher exact test. Continuous variables were compared
y using paired and unpaired nonparametric tests as
ppropriate. The calculated numbers of T cells of
ecipient origin after transplantation were log-trans-
ormed, and linear regression analysis was performed
o compare the rate of decrease in patients with and
ithout aGVHD. Nonparametric correlation (Spear-
an) was used to correlate the T-cell chimerism in PB
nd BM and to correlate the graft CD4/CD8 T-cell
atio with the ratio of the donor T cells after trans-
lantation. All calculations, regressions, and compar-
sons were performed with GraphPad Prism version
.00 for Windows (GraphPad Software, San Diego,
A). A P value .05 was considered signiﬁcant.
ESULTS
mmunosuppression, GVHD, and Follow-up
The tapering regimen for cyclosporine was not
trictly followed in all patients (Table 1). In 3 patients,
yclosporine was changed to tacrolimus before day
100 because of nausea and vomiting (patient 656;
ay 16), liver toxicity of cyclosporine (patient 662;
ay 27), and thrombotic thrombocytopenic purpura
patient 760; day 49). Acute GVHD grades II to IV
ccurred in 59% of the patients, with a median onset
n day 33 (Table 1). Eight patients (patients 636,
56, 662, 666, 674, 688, 715, and 780) died on day
339
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3297, 125, 72, 267, 38, 659, 178, and
142, respectively. As analyzed on September 12,
003, the median follow-up in the surviving patients
as 670 days (range, 319-1263 days).
onor Lymphocyte Infusion
In 3 patients, DLI (1  107 CD3 cells per kilo-
ram) was given within the ﬁrst year after transplan-
ation. The reasons for DLI were progression of the
alignant disease (patient 682; day 116), low donor
-cell chimerism (patient 692; day 115), and the
ombination of disease progression and low donor
-cell chimerism (patient 715; day 84).
himerism
The kinetics of donor chimerism development dif-
ered in the 3 cell populations studied (Figure 1). The
onor CD4 T-cell chimerism was higher than the
onor CD8 T-cell chimerism on day 7 (P  .007;
ilcoxon matched pairs test). From day 14, no
igniﬁcant differences in CD4 and CD8 T-cell
himerism were observed. Both the CD4 and the
D8 T-cell chimerism were higher than the granu-
ocyte chimerism on day 7 and 14 (P  .0001;
ilcoxon matched pairs test), but complete donor
himerism was generally reached earlier in the gran-
locyte compartment, with a median of 42 days
range, 14-104 days), than within the T cells, where
he medians were 154 days (range, 14-378 days) for
he CD4 T cells and 120 days (range, 14-378 days)
or the CD8 T cells. No patients rejected their
rafts, but patient 715 had a relapse of acute myeloid
eukemia on day 56 and subsequently had a decrease
n the level of donor granulocyte chimerism (Figure
c). Tapering of cyclosporine, DLI, or both was used
n several cases, with the purpose of converting a low
evel of donor T-cell chimerism to complete donor
himerism. In patient 708, a decrease in the donor
D8 T-cell chimerism led to tapering of cyclospor-
ne, and subsequently both T-cell subsets became of
omplete donor origin (Figure 2a). In patient 692, the
onversion to complete donor T-cell chimerism oc-
urred only after DLI (Figure 2b). In patient 715, the
iscontinuation of cyclosporine or DLI had no effect
ither on the level of donor T-cell chimerism or on
he disease burden (Figure 2c). The value for T-cell
himerism in the PB very accurately reﬂected the
alue in the BM and showed a strong correlation both
n day 28 (R  0.91 and P  .0001 for the CD4 T
ells; R  0.82 and P  .0002 for the CD8 T cells)
nd on day 56 (R  0.87 and P  .0001 for the
D4 T cells; R  0.96 and P  .0001 for the CD8
cells; data not shown). The donor granulocyte chi-
erism in most of the BM samples showed 95%
onor cells, but in patient 715, the donor granulocyte t
40himerism on the day of relapse was markedly lower in
he BM (77%) than in the PB (99%).
The occurrence of aGVHD did not seem to in-
uence the donor chimerism development in the
ranulocyte compartment (Figure 3a), whereas pa-
ients who developed clinically signiﬁcant aGVHD
grades II-IV) seemed to have a faster increase in the
egree of donor T-cell chimerism when compared
ith patients who did not experience aGVHD (Figure
b and 3c). The relationship between aGVHD and
onor T-cell chimerism was further studied in 13 of
4 patients who experienced aGVHD grades II to IV
nd for whom data on the donor T-cell chimerism
efore and after the onset of aGVHD were available
Figure 4). In most patients, aGVHD occurred in the
ontext of mixed chimerism, and both the CD4 and
D8 donor T-cell chimerism increased signiﬁcantly
uring aGVHD (P  .0002 and P  .019, respec-
igure 1. Donor T-cell and granulocyte chimerism after nonmy-
loablative HSCT. Chimerism analysis of CD4 T cells (a), CD8
cells (b), and granulocytes (c). The horizontal bar in each group
f data points represents the median.ively; Wilcoxon matched pairs test).
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Batient and Donor T-Cell Counts
Measurement of both chimerism and absolute T-
ell subset counts enabled us to calculate the absolute
umber of CD4 and CD8 T cells of recipient and
onor origin after transplantation. Because the studies
f donor T-cell chimerism had suggested a more rapid
ncrease in the patients who developed aGVHD
rades II to IV, we investigated whether the same
elationship was present for the absolute numbers of
onor T cells. The patients were divided on the basis
igure 2. Effect of cyclosporine taper and DLI on T-cell chimer-
sm. Chimerism development of CD4 T cells, CD8 T cells, and
ranulocytes in patient 708 (a), patient 692 (b), and patient 715 (c).
SP, cyclosporine; DLI, donor lymphocyte infusion. *Patient 715
eceived a second NST with cells from the original donor. The
atient died 62 days after the second transplantation because of a
ew relapse of acute myeloid leukemia.f the occurrence of aGVHD, and the increase in d
B & M Tonor T-cell counts and decrease in patient T-cell
ounts were studied (Figure 5a and 5b). In the ﬁrst 4
eeks after transplantation, both the CD4 and the
D8 donor T-cell counts resembled the observa-
ions performed for the chimerism data, with a ten-
ency toward higher counts in the patients who de-
eloped aGVHD (Figure 5a and 5b). However, when
he data for the individual time-points were analyzed,
his difference was signiﬁcant only for the CD8 T
ells on day14 (P .01; Mann-Whitney test; Figure
c). There was a clear correlation between the CD4/
D8 ratio of the grafts and the CD4/CD8 ratio of the
igure 3. Donor chimerism in patients with and without acute
VHD. Donor chimerism (mean and SEM [error bars]) of granu-
ocytes (a), CD4 T cells (b), and CD8 T cells (c) in patients with
GVHD grades 0 to I and grades II to IV.onor T cells on day7 (R 0.75; P .0005) but not
341
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3n day 14 (R  0.25; P  .35; data not shown). We
ompared the recipient T-cell counts obtained before
onditioning with the recipient-derived T-cell counts
n day 7 (Figure 5a and 5b). Both subsets were
educed (P  .0006 for the CD4 T cells and P 
0001 for the CD8 T cells; Wilcoxon matched pairs
est), but the CD4 T-cell counts were less reduced
median, 32%; range, 6%-139% of the pretransplan-
ation value) than the CD8 T-cell counts (median,
1%; range, 2%-63%; P  .0003; Wilcoxon matched
airs test). No difference in this reduction was ob-
erved between patients who did or did not develop
GVHD (P  .9 for both subsets; Mann-Whitney
est). Beyond day7, we analyzed the rate of decrease
f T cells of recipient origin in the 2 groups of patients
y linear regression analysis of the log-transformed
ecipient T-cell counts. In the period when most pa-
ients experienced aGVHD, ie, between days 7 and
56, the slopes of the regression lines were compared.
e observed that there was a trend toward a higher

igure 4. Donor T-cell chimerism before and after the onset of
cute GVHD. Donor CD4 T-cell chimerism (a) and CD8 T-cell
himerism (b) before and after the onset of aGVHD grades II to IV
n 13 patients. The unique patient number for each patient is
hown.ate of decrease of CD4 T cells of recipient origin H
42Figure 5d) and that the CD8 T cells of recipient
rigin disappeared faster in patients with aGVHD
rades II to IV than in patients without aGVHD (P 
016; Figure 5e).
redictive Value of Early Measurements of
himerism and T-Cell Counts
As mentioned previously and as shown in Figure
c, the CD8 donor T-cell count on day 14 was
igher in patients who developed aGVHD when com-
ared with patients who did not experience this com-
lication. To analyze the predictive value of the CD8
onor T-cell count on day 14 for the subsequent
ccurrence of aGVHD, we divided the patient popu-
ation in 2 by using the median value of this variable
0.0429  106 cells per milliliter). The cumulative
ncidence of aGVHD in the 2 groups of patients was
hen estimated by use of Kaplan-Meier statistics and
ompared by using the log-rank test (Figure 5f).
hree patients were not included in this analysis: in
atient 633 and patient 666, no chimerism data on day
14 were available, and patient 674 had the onset of
GVHD on day 7. These patients were therefore
xcluded. The same analysis was performed for the
onor CD8 T-cell chimerism and the total CD8
-cell count on day 14. We found that whereas
either donor CD8 T-cell chimerism alone nor the
otal CD8 T-cell count on day 14 alone could
redict the occurrence of aGVHD (P  .25 and P 
08, respectively), the combined effect of these 2 fac-
ors, ie, the donor CD8 T-cell count, predicted
GVHD development (P  .003; Figure 5f). Factors
uch as the infused CD3 cell number and recipient
ge are known risk factors for the development of
GVHD. We did not observe any relationship be-
ween the donor CD8 T-cell count on day 14 and
ther possible risk factors for the development of
GVHD (Table 2). A multivariate analysis of a larger
ohort of patients is, however, needed to examine
hether the donor CD8 T-cell count on day 14 is
n independent risk factor for the development of
GVHD in this setting.
ISCUSSION
In HLA-identical NST, the curative principle is
he GVT effect mediated by the donor T cells. The
onor T cells may, however, also mediate GVHD,
hich is a serious complication of this treatment. In
his study, we investigated the development of donor
himerism in blood and BM after NST and focused
n relations between aGVHD; donor granulocyte,
D4, and CD8 T-cell chimerism; and the absolute
umbers of donor and recipient T cells. With use of a
onmyeloablative regimen developed at The Fred
utchinson Cancer Research Center [6,14], 24 pa-
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Bients underwent transplantation with PBSC from
LA-identical sibling donors. Acute GVHD grade II
igure 5. T-cell counts in patients with and without acute GVHD.
D8 T cells (b) of donor and recipient origin in patients with aG
ines in (a) and (b) represent the 5th percentile of the counts in 51 he
n 21 patients with aGVHD grades 0 to I and grades II to IV. The ho
ine represents the median of the 21 patients (0.0429 106 donor CD
inear regression analysis of the log-transformed recipient CD4 T
atients with aGVHD grades 0 to I and grades II to IV is shown. M
ines were compared, and the P values are shown. f, Kaplan-Meier pl
donor CD8T-cell count less than or equal to or greater than the m
y using the log-rank test, and the P value is shown.o IV occurred in 59% of the patients. Similar or t
B & M Tlightly lower incidences of aGVHD were reported by
he Seattle consortium when this regimen was used in
te numbers (mean and SEM [error bars]) of CD4 T cells (a) and
rades 0 to I and grades II to IV are shown. The horizontal dotted
onors. c, Comparison of the donor CD8 T-cell count on day14
l bar in each group of data points represents the median. The dotted
ells per milliliter). The P value of the Mann-Whitney test is shown.
ounts (d) and CD8 T-cell counts (e) from day 7 to day 56 in
lues and SEM (error bars) are shown. The slopes of the regression
e cumulative incidences of aGVHD grades II to IV in patients with
on day14. The cumulative incidences of aGVHD were comparedAbsolu
VHD g
althy d
rizonta
8T c
-cell c
ean va
ot of th
edianhe HLA-identical setting [6,14,19,20].
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3The granulocyte donor chimerism was lower than
he T-cell chimerism for the ﬁrst 2 weeks. After that,
rapid increase in donor granulocyte chimerism oc-
urred, with the result that complete donor granulo-
yte chimerism was reached earlier than complete
onor T-cell chimerism. A similar pattern of the de-
elopment of donor granulocyte chimerism has been
eported previously by others who have used the same
ransplantation regimen [21-23], and it may reﬂect the
hort life span of the infused granulocytes. An increase
n donor granulocyte chimerism in the PB must await
he generation of new granulocytes from the engrafted
recursors in the BM. In contrast, the infused donor T
ells may undergo peripheral expansion and thereby
ncrease the donor chimerism early after transplanta-
ion. The delay in the T cells to become entirely of
onor origin when compared with the granulocytes
as been reported previously [13,24]. The kinetics of
he development of donor chimerism in PB cell sub-
opulations may be affected by the conditioning reg-
men used. Using a regimen based on cyclophospha-
ide and ﬂudarabine, Childs et al. [3] observed that
00% donor T-cell chimerism generally occurred be-
ore complete donor myeloid chimerism. Valcarcel et.
l. [25] found that patients conditioned with melpha-
an and ﬂudarabine were complete donor chimeras in
oth T cells and granulocytes on day 30, whereas
atients conditioned with busulphan and ﬂudarabine
ere mixed T-cell chimeras and complete donor gran-
locyte chimeras at the same time-point.
Canine and murine studies have shown that a state
f mutual graft/host tolerance and absence of GVHD
an be created by the induction of stable mixed chi-
erism [26-28]. In humans, it is still an open question
hether mixed chimerism per se protects the recipient
gainst GVHD. Childs et al. [3] reported that
GVHD occurred only in patients who were 100%
onor T-cell chimeras, whereas Mattsson et al. [13]
able 2. Possible GVHD-Associated Factors versus the Day 14 Dono
Variable
Day 14 CD8 Do
Count <0.0429 
(n  11), Median
retransplantation characteristics
Recipient age (y) 51 (34-63
Donor age (y) 52 (41-63
Previous chemotherapy regimens 4 (2-7)
Previous autotransplantation 5
Female donor to male recipient 4
raft composition
Infused CD3 T cells  108/kg 3.7 (2.2-5.
Infused CD4 T cells  108/kg 2.8 (1.7-3.
Infused CD8 T cells  108/kg 1.1 (0.5-1.
Infused CD34 cells  106/kg 7.1 (3.8-14
The categorical variables previous autotransplantation and female d
other possible risk factors were considered as continuous variabound that mixed chimerism was common at the time l
44f onset of aGVHD. In our study, most of the patients
xperienced aGVHD when they were still mixed T-
ell chimeras, but a signiﬁcant increase in the degree
f donor T-cell chimerism was observed when the
atients had aGVHD.
The toxicity of the conditioning regimen and the
lloreactivity of the donor T cells may both lead to the
limination of the recipient T cells after NST. Storb
t al. [29] and Georges and Storb [30] have proposed
model in which alloreactive donor T cells eliminate
he recipient lymphohematopoietic tissues during
ubclinical or clinical graft-versus-host reactions,
hich results in an increase in the donor T-cell chi-
erism. In this study, we observed a reduction in the
cells of recipient origin; this was most pronounced
n the CD8 T-cell subset when we compared the
retransplantation values and the values on day 7
Figure 5a and 5b). Because of the lack of difference in
his reduction between patients who developed
GVHD and patients who did not, we ﬁnd it likely
hat the reduction in T cells of recipient origin until
ay 7 is mainly due to the toxicity of the condition-
ng regimen and that the CD8 T cells may be more
ensitive to this toxicity than the CD4 T cells. How-
ver, both the ﬁnding that the donor T-cell chimerism
ncreased during the occurrence of aGVHD (Figure
) and the observation of a faster rate of disappearance
f recipient CD8 T cells after day 7 in patients
ho experience aGVHD grades II to IV (Figure 5e)
upport the hypothesis by Storb et al.
In allogeneic HSCT with myeloablative condi-
ioning, the onset of aGVHD is generally observed
ithin the ﬁrst month after transplantation, and in a
arge study of HLA-identical BM transplantation
BMT), aGVHD occurred with a median onset of 16
ays after transplantation [31]. In contrast, we found
hat aGVHD occurred rather late, with a median
nset of 33 days after transplantation. Similarly, in a
T-Cell Count
Cell
L
e)
Day 14 CD8 Donor T-Cell
Count >0.0429  106/mL
(n  10), Median (Range) P Value*
49 (34-57) .34
47 (36-68) .67
5 (1-10) .89
6 .67
3 .99
3.6 (2.8-6.8) .74
2.4 (2.0-4.8) .97
1.3 (0.8-2.0) .41
5.8 (2.6-21.7) .55
o male recipient were compared by using the Fisher exact test. The
were compared by using the Mann-Whitney test.r CD8
nor T-
106/m
(Rang
)
)
1)
9)
4)
.4)
onor t
les andarger cohort of recipients of HLA-identical sibling
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Donor CD8 T-Cell Count on Day 14 Predicts Risk of Acute GVHD
BST for which the same postgrafting immunosup-
ression regimen was used, the median day of onset of
GVHD was day 40 [6]. In that report, the level of
onor T-cell chimerism in the PB on day 28 pre-
icted the subsequent occurrence of aGVHD grades
I to IV. This relationship was, however, not seen
hen more patients were analyzed [19]. In this study,
he donor T-cell chimerism on day 28 could not
redict the occurrence of aGVHD; instead, we
howed that the donor CD8 T-cell count on day
14 had predictive value for the subsequent occur-
ence of aGVHD grades II to IV. The ability to
redict aGVHD on the basis of a blood sample on day
14 and the late occurrence of aGVHD with this
egimen is important for the clinical usefulness of the
btained information, because this leaves ample time
or sample analysis and possible intervention. The
elationship between early T-cell reconstitution and
GVHD has been studied previously in myeloablative
MT in different clinical settings. Gratama et al. [32]
ound a correlation between a low CD4/CD8 T-cell
atio on days 18 to 25 and the occurrence of
GVHD in 24 patients who received HLA-identical
MT with methotrexate as GVHD prophylaxis.
hen the authors subsequently analyzed a cohort of
3 recipients of HLA-identical BMT with cyclospor-
ne as GVHD prophylaxis, they did not observe this
orrelation [33]. Soiffer et al. [34] reported in a study
f 136 recipients of CD6 T-cell depleted BMT, in
hom no immunosuppressive agents were used as
VHD prophylaxis, that a high percentage of CD8
cells among the PB mononuclear cells in week 2
fter transplantation identiﬁed patients with a high
isk of aGVHD. In our study, the donor CD8 T-cell
ount on time-points other than day 14 could not
redict the occurrence of aGVHD. The ﬁnding of a
trong correlation between the CD4/CD8 ratio of the
rafts and the CD4/CD8 ratio of the donor T cells on
ay 7 but not on day 14 could indicate that in the
rst week after transplantation, the donor T cells
ndergo lymphopenia-induced homeostatic prolifera-
ion at a similar rate in most patients. In the second
eek after transplantation, differences in the rate of
xpansion of alloreactive donor T cells could then
xplain why the day 14 donor T-cell count predicts
GVHD.
To reduce the occurrence of GVHD, the Seattle
onsortium has extended the full-dose cyclosporine
reatment in all patients from the original 35 days after
ransplantation to the presently used 56 days [30]. The
egimen for cyclosporine taper depends on the risk of
isease progression. In patients with aggressive dis-
ase, the taper is rapid, with discontinuation on day
75, whereas in patients with indolent disease, cyclo-
porine is discontinued on day 180 [30]. Individual-
zation of the immunosuppression on the basis of a
ombination of the risk of aGVHD and the risk of
B & M Tisease progression could improve the treatment re-
ults if the incidence of aGVHD in patients with high
isk could be reduced. We think, however, that our
esults need to be conﬁrmed in a larger cohort of
atients before they can be used in the clinical setting.
ne way to reduce the incidence of aGVHD in high-
isk patients could be to increase the duration and
ossibly the dose of mycophenolate mofetil. The Se-
ttle consortium has already modiﬁed the immuno-
uppressive regimen in this way for all patients in the
nrelated donor setting [10].
In conclusion, we found that chimerism analysis of
ubpopulations of leukocytes is important in the treat-
ent of patients undergoing NST. Chimerism studies
ay also contribute to the understanding of the rela-
ionship between clinical GVHD, graft-versus-lym-
hohematopoietic tissue reactions, and the GVT effect.
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